Skip to content
Screener

Prelude Therapeutics PRLD Q3 2025 earnings

Reported November 12, 2025 · Before market open

Revenue$6.5MMiss by $14.0M
EPS-$0.26Beat by $0.09
Revenue estimate$20.5M
EPS estimate-$0.35

Next report

Nov 11, 2026 (in 2 months)
Revenue estimate$35.3M
EPS estimate-$0.16

FAQ

When did Prelude Therapeutics report Q3 2025 earnings?
Prelude Therapeutics (PRLD) reported Q3 2025 earnings on November 12, 2025 before market open.
What were Prelude Therapeutics's Q3 2025 revenue and EPS?
Prelude Therapeutics reported revenue of $6.5M and eps of $-0.26 for Q3 2025.
Did Prelude Therapeutics beat estimates in Q3 2025?
Revenue missed the consensus estimate of $20.5M by $14.0M. EPS beat the consensus estimate of $-0.35 by $0.09.
How did Prelude Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 116.7% from $3.0M a year earlier and eps grew 39.5% from $-0.43.
Where can I find Prelude Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-275871) and the 10-Q periodic report (0001193125-25-275887) directly on SEC EDGAR. The filing index links above go to sec.gov.